---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083629"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:14:33.808328+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q2 ARCALYST revenue $54.5M; raises FY2023 guidance to $220-230M

## Summary
- Q2 total revenue $71.5M (vs $27.0M YoY), ARCALYST net product revenue $54.5M (vs $27.0M YoY).
- Net income $15.0M vs net loss $20.0M YoY; includes $16.2M tax benefit from valuation allowance release.
- 2023 ARCALYST revenue guidance raised to $220-230M from $200-215M; cash runway extended into at least 2027.
- Over 1,250 prescribers have written ARCALYST; average therapy duration ~20 months; 45% of patients restarted within 8 weeks.
- KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024; $15.0M milestone from Genentech vixarelimab agreement.

## SEC filing metadata
- accession: 0001104659-23-083629
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/0001104659-23-083629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/tm2321659d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083629
- JSON: https://secwatch.observer/filing/0001104659-23-083629.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083629.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported quarter ended June 30, 2023 results: revenue $71.5 million, net income $15.0 million. Guidance raised.
  - Period: quarter ended June 30, 2023
  - Revenue: $71.5 million
  - Net income: $15.0 million
  - Guidance: raised
  - Result: reported results
  source text: Financial Results • Total revenue for the second quarter of 2023 was $71.5 million, compared to $27.0 million for the second quarter of 2022. - Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST net product revenue and $17.0 million in license and collaboration revenue, compared to $27.0 million in ARCALYST net product revenue and $0.0 million in license and collaboration revenue for the second quarter of 2022. • Total operating expenses for the second quarter of 2023 were $74.6 million, compared to $46.3 million for the second quarter of 2022. - Total operating expenses for the second quarter of 2023 included $6.5 million in non-cash, share-based compensation expense, compared to $6.7 million for the second quarter of 2022. • Net income for the second quarter of 2023 was $15.0 million, compared to a net loss of $20.0 million for the second quarter of 2022. - Net income for the second quarter of 2023 included a $16.2 million tax benefit primarily due to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923083629/0001104659-23-083629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.